Skip to main content
Premium Trial:

Request an Annual Quote

Myriad Moving Eight Protein-Based Tests to Market; Priorities Include AD, Kidney Damage, Colon Cancer


This story originally ran on Nov. 4.

Myriad Genetics has eight protein-based tests progressing toward commercialization, company officials said this week on a conference call discussing the firm's earnings for the quarter ended Sept. 30.

These offerings, which are being developed through the company's Myriad RBM division – formed by the $80 million purchase this April of protein-biomarker discovery firm Rules-Based Medicine (PM 4/29/2011) – include five tests that have been designated as high priority for commercialization, Myriad CEO Peter Meldrum said on the call.

According to Meldrum, these five tests include: a product for early detection of kidney damage in diabetes patients; a diagnostic for distinguishing between bipolar disorder and major depression; a test for the early detection of kidney transplant rejection; a test for differentiating between patients with mild cognitive impairment and Alzheimer's disease; and a blood-based diagnostic for the early detection of colon cancer.

Meldrum also noted opportunities in protein-based testing presented by Myriad's investment in molecular diagnostic firm Crescendo Bioscience, which specializes in tests for autoimmune and inflammatory diseases like rheumatoid arthritis. In September, Myriad made a $25 million debt investment in Crescendo that gives it a three-year option to purchase the company (PM 9/9/2011).

Calling the investment an "attractive, low-risk strategy to position Myriad in the autoimmune and inflammatory disease markets," Meldrum highlighted the firm's initial product, Vectra DA – a laboratory-developed test that measures levels of 12 proteins in blood to assess rheumatoid arthritis activity.

For the quarter, the first of the company's 2012 fiscal year, Myriad RBM generated $6.5 million in revenues, which, Meldrum noted, trended toward the upper end of the company's full-year revenue guidance for the division of between $24 and $26 million.

The company's total revenues were $110.5 million for the quarter, up 20 percent from $91.9 million in the year-ago period.

The Scan

Could Mix It Up

The US Food and Drug Administration is considering a plan that would allow for the mixing-and-matching of SARS-CoV-2 vaccines and boosters, the New York Times says.

Closest to the Dog

New Scientist reports that extinct Japanese wolf appears to be the closest known wild relative of dogs.

Offer to Come Back

The Knoxville News Sentinel reports that the University of Tennessee is offering Anming Hu, a professor who was acquitted of charges that he hid ties to China, his position back.

PNAS Papers on Myeloid Differentiation MicroRNAs, Urinary Exosomes, Maize Domestication

In PNAS this week: role of microRNAs in myeloid differentiation, exosomes in urine, and more.